Search Results for “vaccine” – Page 29 – media

There is no Summit in China

Innovative drugs are a gamble, a big gamble. Once the research and development fails, the stock price collapses and financing is unavailable. On the contrary, if the gamble is won, it is not impossible for the stock price to soar. Especially in the US stock market, it has always been so violent. For the losers, there are only two options: disband on the spot or fight back. The so-called fight back means finding a way to start the next round of innovation gambling. This requires both money and the courage to gamble. Summit is an old “gambler” who plans to gamble again. After its establishment in 2003, Summit focused on the anti-infection field, and its core product was benchmarked against vancomycin, the “last line of defense for antibiotics.” It landed on Nasdaq in 2015, but because the core product ridinilazole did not perform well in the final clinical data, the ...
- Source: drugdu
- 80
- September 21, 2024
1.5 billion US dollars! Capricor Therapeutics partners with Nippon Pharmaceutical Co., Ltd

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. On September 17, 2024, Capricor Therapeutics, a biotechnology company developing transformed cell and exosome therapies for the treatment of rare diseases, announced that it had signed a binding term sheet with Nippon Pharma. The terms state that Nippon Pharma will commercialize and distribute Capricor’s main asset, deramiocel, in Europe for the treatment of Duchenne muscular dystrophy (DMD). Capricor will receive a $15 million equity investment at a 20% premium and a $20 million advance payment upon signing the final agreement. The potential milestone amount is as high as $715 million, with product revenue accounting for double digits. The total ...
- Source: drugdu
- 66
- September 19, 2024
WHO chief hails ‘massive success’ of polio campaign amid tragic reality

WHO chief Tedros Adhanom Ghebreyesus tweeted that it had been “a massive success amidst a tragic daily reality of life” for more than two million Gazans who have been caught up in the intense fighting since last October’s terror attacks by Hamas unleashed the war in Gaza. In three phases over twelve days, from 1 to 12 September, UN agencies and partners provided novel oral polio vaccine type 2 (nOPV2) to some 558,963 children, reaching families living in shelters, tents and camps for the displaced. Tweet URL Richard Peeperkorn, WHO Representative for the occupied Palestinian territory applauded the “incredible resilience” of health and community workers in conducting the campaign “at an unprecedented scale and speed under the toughest conditions” in the war-battered enclave. “Swift action by the Global Polio Eradication Initiative – from the moment the virus was detected to the launch of the vaccination campaign – speaks to the ...
- Source: drugdu
- 70
- September 16, 2024
Increasing Investment in R&D Innovation to Deepen Product Competitive Moats

CSPC Pharmaceutical Group has achieved significant milestones in research and development, securing conditional approval for its self-developed Class 1 new drug, Enlansub, and for the injectable version of Rayzoprazole. The company has also received approval for clinical trials in the U.S. for its antibody-drug conjugate, clinical trial approval for its mRNA vaccine against respiratory syncytial virus, and clinical trial approval for the first CAR-T cell injection based on mRNA-LNP technology. As an innovation-driven enterprise and a key player in the national industrial chain, CSPC continues to enhance its R&D investments, elevate its international influence, and fortify its product competitive edge. This year, various in-development drugs have reached key progress points, with some approved for market launch or clinical trials both domestically and internationally. Currently, CSPC is conducting over 130 innovative drug projects, with more than 50 new drugs expected to be launched in the next five years. Comprehensive Market Coverage ...
- Source: drugdu
- 76
- September 14, 2024
Another new COPD drug is coming

On September 6, GlaxoSmithKline (GSK) announced that its Phase 3 MATINEE study of its IL-5 antibody Nucala (mepolizumab) in the treatment of COPD achieved positive results. Compared with the placebo group, the Nucala treatment group achieved a statistically significant reduction in the annualized rate of moderate to severe exacerbations, but specific data have not yet been released. Two months ago, two COPD drugs with new mechanisms: ensifentrine and dupilumab were approved for marketing in the United States and Europe, refreshing the treatment model of this severe respiratory disease. Mepolizumab is expected to join this new round of competition. COPD: The third leading cause of death in humans Chronic obstructive pulmonary disease (COPD), referred to as COPD, is a common, preventable and treatable heterogeneous disease. According to statistics from the World Health Organization, COPD has become the third leading cause of death in humans, with about 11% of people dying from ...
- Source: drugdu
- 68
- September 14, 2024
The highest increase was 103398%! The revenue of these pharmaceutical companies soared

In September, the 2024 semi-annual reports of various companies have basically been disclosed. According to statistics from Cyber Blue, among the 493 A-share listed pharmaceutical companies (according to the industry classification of Tonghuashun, the same below), the number of companies with year-on-year decline and growth is close to “50-50” – 242 pharmaceutical companies have a year-on-year decline in revenue, accounting for 49% of the total; 252 have an increase in revenue, accounting for 51% of the total. Among the 242 pharmaceutical companies whose revenue decreased compared with the same period last year, 40% of them fell by less than 10%; there were 12 companies with a decline of more than 50%, of which the company with the largest decline had a year-on-year revenue decline of more than 97%. Among the 252 pharmaceutical companies with year-on-year revenue growth, 183 had an increase of less than 20%, accounting for ...
- Source: https://mp.weixin.qq.com/
- 55
- September 12, 2024
In 2024, consumer healthcare will have a hard time

According to statistics from Guangdong Securities, the domestic consumer healthcare market size corresponds to a trillion-level market. Among them, the market size of specialized medical fields such as ophthalmology, stomatology, and assisted reproduction can reach 382.62 billion yuan, and is expected to reach 605.88 billion yuan in 2025; the market size of the medical beauty field has reached 226.7 billion yuan, and is expected to reach 352.9 billion yuan in 2025. In such a vast market, growth should be the first priority. However, after the epidemic, the expected consumption recovery and rebound have not arrived. Since the third quarter of last year, the overall economic environment has continued to weaken, and the operating pressure of sub-industries such as medical services, consumer equipment, and medical beauty with consumer attributes has increased, and most of them have not met expectations. This was particularly evident in the second quarter of this year, and ...
- Source: drugdu
- 90
- September 7, 2024
Two innovative medical devices have been approved for market launch

On September 3rd, the National Medical Products Administration announced that it has recently approved the registration applications for two innovative products, the “Navigation Positioning Microwave Ablation System” of True Health (Zhuhai) Medical Technology Co., Ltd. (hereinafter referred to as “True Health Medical”) and the “Hepatitis B Virus Surface Antigen (HBsAg) Detection Kit (Chemiluminescence Method)” of Fuji Ruibiou Co., Ltd. (hereinafter referred to as “Fuji Ruibiou”). True Health Medical: International First Product Founded in 2018, True Health Medical is a national high-tech enterprise specializing in the research and production services of surgical robots. Based on artificial intelligence technology, it integrates intelligent robot systems into the diagnosis and treatment process through the close integration of industry, academia, research, and medicine, achieving a comprehensive medical technology system with precise puncture of soft tissue lesions throughout the body as a diagnostic and treatment method. Precise puncture is a means to deliver minimally invasive treatment ...
- Source: drugdu
- 90
- September 6, 2024
AstraZeneca China’s structure will be adjusted

According to various sources in the industry, AstraZeneca China’s biopharmaceutical business BBU and omnichannel business unit structure will undergo a series of adjustments on October 1 this year. AstraZeneca China’s biopharmaceutical business and omnichannel business unit will be officially merged to form a new AstraZeneca China biopharmaceutical business (BBU). Merge the respiratory inhalation business unit, respiratory atomization business unit and digestive business unit to form the respiratory digestive business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit to form the respiratory and autoimmune biopharmaceuticals, vaccines and immunotherapy business units. According to incomplete statistics, this is at least the third adjustment of AstraZeneca China this year. “Adjustment” seems to be the key to AstraZeneca China’s performance development. AstraZeneca once said that the new map will add momentum to the long-term development of its business. ...
- Source: drugdu
- 77
- September 6, 2024
Jimin Health aims at the new biomedical technology track

As one of the first hospitals to enter the Boao Lecheng International Medical Tourism Zone in Hainan, the Boao International Hospital of Jimin Health, relying on the policy advantage of “early and pilot implementation” of the zone, has focused its R&D efforts on two major R&D pipelines of adipose-derived mesenchymal stem cells and dendritic cells in the field of cellular therapeutic drugs. Tian Yunfei, director and president of Jimin Health, recently said in an interview with China Securities Journal, “Based on the long-term optimism for the development prospect of cell therapy drugs, Jimin Health will focus on the research and development of Boao International Hospital’s cell therapy drug pipeline in the future.” Joining hands with stem cell experts JiminHealth’s 2024 semi-annual report disclosed the appointment of Jonathan Robert Lakey as the chief scientist of the International Regenerative Medicine Research Center of Boao International Hospital, a controlling subsidiary, and that the ...
- Source: drugdu
- 67
- September 4, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.